68Ga-P3 PET/CT Imaging in Malignancy

Recruiting now · Not applicable

Conditions studied: Neoplasms

In brief

Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein that consists of 750 amino acids. It is highly expressed on most prostate cancer cells and neovascular endothelial cells of tumors, making PSMA a highly specific and significant imaging target for malignancies. \[68Ga\]P3, a novel molecular probe of PET imaging agent that targets PSMA, can be used in the diagnosis and research of a wide variety of PSMA high-expression malignanciesr.

Key facts

Study ID

NCT05887687

Run by

Peking University First Hospital

People needed

350

Starts

2023-05-20

Expected to finish

2025-07-31

Last updated by the study team

2024-11-07

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• patients with confirmed or suspected cancer; 18F-FDG PET/CT within 1 week; Signed written informed consent

You may not qualify if…

• Pregnant and lactating women; Female patients plan to become pregnant within 6 months.

Where it is running

• Peking University First Hospital — Beijing, Beijing Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.